BR112022019914A2 - Coadministração de mirdametinibe e lifirafenibe para uso no tratamento de cânceres - Google Patents
Coadministração de mirdametinibe e lifirafenibe para uso no tratamento de cânceresInfo
- Publication number
- BR112022019914A2 BR112022019914A2 BR112022019914A BR112022019914A BR112022019914A2 BR 112022019914 A2 BR112022019914 A2 BR 112022019914A2 BR 112022019914 A BR112022019914 A BR 112022019914A BR 112022019914 A BR112022019914 A BR 112022019914A BR 112022019914 A2 BR112022019914 A2 BR 112022019914A2
- Authority
- BR
- Brazil
- Prior art keywords
- mirdametinib
- lifirafenib
- treatment
- cancer
- pharmaceutically acceptable
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063005153P | 2020-04-03 | 2020-04-03 | |
| PCT/US2021/025551 WO2021202981A1 (en) | 2020-04-03 | 2021-04-02 | Co-administration of mirdametinib and lifirafenib for use in treating cancers |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112022019914A2 true BR112022019914A2 (pt) | 2022-12-13 |
Family
ID=75674969
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112022019914A BR112022019914A2 (pt) | 2020-04-03 | 2021-04-02 | Coadministração de mirdametinibe e lifirafenibe para uso no tratamento de cânceres |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US20230128315A1 (https=) |
| EP (1) | EP4125842B1 (https=) |
| JP (2) | JP7748386B2 (https=) |
| KR (1) | KR20230048476A (https=) |
| CN (1) | CN116194095B (https=) |
| AU (1) | AU2021246141A1 (https=) |
| BR (1) | BR112022019914A2 (https=) |
| CA (1) | CA3174223A1 (https=) |
| CL (1) | CL2022002682A1 (https=) |
| CO (1) | CO2022015891A2 (https=) |
| DK (1) | DK4125842T3 (https=) |
| ES (1) | ES2985012T3 (https=) |
| FI (1) | FI4125842T3 (https=) |
| HU (1) | HUE067894T2 (https=) |
| IL (1) | IL296878A (https=) |
| MX (1) | MX2022012351A (https=) |
| PE (1) | PE20231211A1 (https=) |
| PL (1) | PL4125842T3 (https=) |
| PT (1) | PT4125842T (https=) |
| TW (1) | TWI893097B (https=) |
| WO (1) | WO2021202981A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3254428A1 (en) * | 2022-03-17 | 2023-09-21 | SpringWorks Therapeutics Inc. | TREATMENT OF PLEXIFORM NEUROFIBROMAS (NP) ASSOCIATED WITH TYPE 1 NEUROFIBROMATOSIS (NF1) IN PEDIATRIC PATIENTS WITH MIRDAMETINIB |
| WO2023178276A1 (en) * | 2022-03-17 | 2023-09-21 | SpringWorks Therapeutics Inc. | Treatment of pancreatic ductal adenocarcinoma with mirdametinib |
| WO2023209611A1 (en) * | 2022-04-26 | 2023-11-02 | Beigene Switzerland Gmbh | Methods of treating cancer with a b-raf inhibitor, in particular lifirafenib |
| JP2025534589A (ja) * | 2022-10-14 | 2025-10-17 | スプリングワークス、セラピューティクス、インコーポレイテッド | がんの治療に使用するための併用 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2013148817A (ru) * | 2011-04-01 | 2015-05-10 | Дженентек, Инк. | Комбинации соединений-ингибиторов акт и мек и способы их применения |
| CN113307805A (zh) * | 2015-04-15 | 2021-08-27 | 百济神州有限公司 | B-raf激酶抑制剂的马来酸盐、其结晶形式、制备方法和用途 |
| WO2019113345A1 (en) * | 2017-12-06 | 2019-06-13 | Spyro Mousses | Combination of cancer therapeutics for treatment of cancer and hyperproliferative diseases |
| EP3560516A1 (en) * | 2018-04-27 | 2019-10-30 | Bergen Teknologioverforing AS | Combination therapy including beta-sitosterol in combination with at least one of a braf inhibitor, a mek inhibitor or an erk inhibitor and methods and use thereof |
-
2021
- 2021-04-02 AU AU2021246141A patent/AU2021246141A1/en active Pending
- 2021-04-02 IL IL296878A patent/IL296878A/en unknown
- 2021-04-02 PT PT217217066T patent/PT4125842T/pt unknown
- 2021-04-02 BR BR112022019914A patent/BR112022019914A2/pt unknown
- 2021-04-02 TW TW110112271A patent/TWI893097B/zh active
- 2021-04-02 DK DK21721706.6T patent/DK4125842T3/da active
- 2021-04-02 CN CN202180036587.XA patent/CN116194095B/zh active Active
- 2021-04-02 KR KR1020227038490A patent/KR20230048476A/ko active Pending
- 2021-04-02 CA CA3174223A patent/CA3174223A1/en active Pending
- 2021-04-02 ES ES21721706T patent/ES2985012T3/es active Active
- 2021-04-02 PE PE2022002181A patent/PE20231211A1/es unknown
- 2021-04-02 WO PCT/US2021/025551 patent/WO2021202981A1/en not_active Ceased
- 2021-04-02 EP EP21721706.6A patent/EP4125842B1/en active Active
- 2021-04-02 FI FIEP21721706.6T patent/FI4125842T3/fi active
- 2021-04-02 HU HUE21721706A patent/HUE067894T2/hu unknown
- 2021-04-02 MX MX2022012351A patent/MX2022012351A/es unknown
- 2021-04-02 JP JP2022560245A patent/JP7748386B2/ja active Active
- 2021-04-02 PL PL21721706.6T patent/PL4125842T3/pl unknown
- 2021-04-02 US US17/995,002 patent/US20230128315A1/en active Pending
-
2022
- 2022-09-30 CL CL2022002682A patent/CL2022002682A1/es unknown
- 2022-11-03 CO CONC2022/0015891A patent/CO2022015891A2/es unknown
-
2025
- 2025-06-18 JP JP2025102055A patent/JP2025120501A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2025120501A (ja) | 2025-08-15 |
| CN116194095A (zh) | 2023-05-30 |
| AU2021246141A1 (en) | 2022-12-01 |
| EP4125842A1 (en) | 2023-02-08 |
| KR20230048476A (ko) | 2023-04-11 |
| ES2985012T3 (es) | 2024-11-04 |
| TW202207910A (zh) | 2022-03-01 |
| WO2021202981A1 (en) | 2021-10-07 |
| CN116194095B (zh) | 2024-09-13 |
| IL296878A (en) | 2022-12-01 |
| HUE067894T2 (hu) | 2024-11-28 |
| CO2022015891A2 (es) | 2023-05-08 |
| JP2023521036A (ja) | 2023-05-23 |
| JP7748386B2 (ja) | 2025-10-02 |
| DK4125842T3 (da) | 2024-07-22 |
| EP4125842B1 (en) | 2024-06-05 |
| PE20231211A1 (es) | 2023-08-17 |
| TWI893097B (zh) | 2025-08-11 |
| CA3174223A1 (en) | 2021-10-07 |
| PL4125842T3 (pl) | 2024-10-14 |
| MX2022012351A (es) | 2023-03-13 |
| CL2022002682A1 (es) | 2023-06-16 |
| US20230128315A1 (en) | 2023-04-27 |
| FI4125842T3 (fi) | 2024-08-06 |
| PT4125842T (pt) | 2024-08-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112022019914A2 (pt) | Coadministração de mirdametinibe e lifirafenibe para uso no tratamento de cânceres | |
| ZA202307538B (en) | Use of a bet inhibitor alone or in combination with fedratinib or ruxolitinib for treating a hematological malignancy such as myelofibrosis | |
| JOP20210171A1 (ar) | مثبطات أزا-غير متجانسة ثنائية الحلقة لـ mat2a وطرق الاستخدام لعلاج السرطان | |
| JOP20210172A1 (ar) | مثبطات أزا-غير متجانسة ثنائية الحلقة لـ mat2a وطرق الاستخدام لعلاج السرطان | |
| MX2022003072A (es) | Uso de pridopidina para el tratamiento de la disminucion funcional. | |
| MX2021004639A (es) | Combinaciones de inhibidores de desmetilasa-1 especifica de lisina (lsd1) para uso en el tratamiento de tumores solidos. | |
| BR112015029491A2 (pt) | derivados de imidazopirrolidinona e seu uso no tratamento de doença | |
| MX381475B (es) | Terapia de combinacion que usa irinotecan liposomal y un inhibidor de poli(adp-ribosa) polimerasa (parp) para el tratamiento del cancer. | |
| EA201650134A1 (ru) | Специфическая сочетанная терапия злокачественных опухолей цитостатиком и его модификатором | |
| NZ723271A (en) | Fused imidazole derivatives useful as ido inhibitors | |
| BR112016007946A2 (pt) | combinação farmacêutica, usos da mesma, de plinabulina e de composição, kits ou mistura e método para tratar e/ou prevenir câncer | |
| PH12020500665A1 (en) | Pladienolide derivatives as spliceosome targeting agents for treating cancer | |
| AR096892A1 (es) | Una combinación farmacéutica para el tratamiento del melanoma | |
| RU2018135973A (ru) | Фармацевтическая комбинация, содержащая метроформин и дигидрокверценин, и ее применение для лечения рака | |
| JOP20200015A1 (ar) | توليفة علاجية من مثبط كيناز تيروسين egfr من الجيل الثالث ومثبط كيناز يعتمد على سيكلين | |
| PH12020500666A1 (en) | Pladienolide compounds and their use | |
| PH12020550462A1 (en) | Cocrystals, pharmaceutical compositions thereof, and methods of treatment involving same | |
| JOP20200014A1 (ar) | توليفة علاجية لمثبط كيناز تيروزين egfr من الجيل الثالث ومثبط raf | |
| RU2018107930A (ru) | Агонисты tlr4, их композиции и применение для лечения рака | |
| BR0309226A (pt) | Métodos para a produção de um efeito de danificação vascular em um animal de sangue quente, e para o tratamento de um câncer envolvendo um tumor sólido em um animal de sangue quente, composição farmacêutica, kit, e, usos de zd6126 ou de um seu sal farmaceuticamente aceitável, e de zd1839 ou de um seu sal farmaceuticamente aceitável | |
| EA201991069A1 (ru) | Комбинированная терапия ингибитором фосфоинозитид-3-киназы и связывающим цинк агентом | |
| BR112023023398A2 (pt) | Usos de um conjugado anticorpo-droga em combinação com um inibidor de checkpoint imune e de uma quantidade eficaz de conjugado anticorpo-droga e um inibidor de checkpoint imune, método para tratar um paciente com câncer urotelial, e, composição farmacêutica | |
| MX2022011171A (es) | Compuestos con actividad inmunomodulatoria y usos terapeuticos de estos. | |
| BRPI0508982A (pt) | uso de azd2171 ou de um sal deste farmaceuticamente aceitável excluindo um sal de maleato de azd2171, composição farmacêutica, kit, método para o tratamento de um cáncer em um animal de sangue quente tal como um ser humano, e, uso de sal de maleato de azd2171 e 5 - fu e cpt - 11 | |
| BRPI0508983A (pt) | uso de azd2171 ou de um sal deste farmaceuticamente aceitável excluido um sal de maleato de azd2171 e um taxano, composição farmacêutica, kit, e, método para a produção de efeito antiangiogênico e/ou de redução da permeabilidade vascular em um animal de sangue quente tal como um ser humano |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06W | Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette] |